Drug Trial Radar · NCT07895238
A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,088
Planned (sponsor's estimate)
Start
Oct 31, 2026
Primary completion
Dec 31, 2032
Study completion Dec 31, 2034
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multicenter, phase III clinical study to compare the efficacy and safety of perioperative treatment with adebrelimab plus platinum-based chemotherapy versus adebrelimab adjuvant therapy in patients with resectable stage II-IIIB non-small-cell lung cancer(NSCLC).
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
Adebrelimab (SHR-1316) + chemotherapyDrug
3 cycles of adebrelimab 1200 mg plus platinum-containing doublet chemotherapy administered every 3 weeks (Q3W); followed by postoperative adjuvant adebrelimab 1200 mg
AdebrelimabDrug
Patients who have undergone curative-intent surgery receive adjuvant chemotherapy, followed by adebrelimab 1200 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- EFSTime frame: Approximately 96 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.